Methergin® (Methylergometrine Maleate)

Methylergometrine maleate acts as a partial agonist at serotonin (5‑HT2) and dopamine receptors in the uterine smooth muscle. This activation raises intracellular calcium levels, leading to sustained uterine contraction, which promotes clot formation and reduces postpartum bleeding.

The specific dose of Methergin® is determined by the prescribing clinician based on the patient’s condition, weight, and response. Dosing regimens are individualized and should follow local clinical guidelines and the prescriber’s judgment.

Methergin® is intended for use after delivery; it is not recommended during active pregnancy. While limited data exist on excretion in breast milk, caution is advised for breastfeeding mothers, and the benefits should be weighed against potential risks.

To order Methergin®, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

The most common alternative uterotonic is oxytocin, which also induces uterine contraction but via oxytocin receptors. Methylergometrine maleate provides a longer‑lasting contraction and is useful when oxytocin alone is insufficient, though it carries a higher risk of hypertension and vasospasm.

Methergin® should be stored below 25 °C, in its original packaging, and protected from moisture. Keep the vial out of direct sunlight and avoid freezing. Follow standard aseptic techniques when preparing for intramuscular or intravenous administration.

Methergin® is administered by a healthcare professional via intramuscular or intravenous injection. The route, injection site, and rate of administration are determined by the clinician according to the clinical situation and patient response.

Serious risks include coronary vasospasm, severe hypertension, myocardial ischemia, pulmonary edema, seizures, and anaphylactic reactions. Immediate medical attention is required if any of these symptoms develop during or after administration.

Methergin® is contraindicated in patients with uncontrolled hypertension, known coronary artery disease, severe liver or kidney impairment, and in those with a history of hypersensitivity to ergot alkaloids. It should also be avoided in women who are still pregnant.